10-Q: ABVC BioPharma Reports Q3 2025 Loss Amid Pipeline Delays

ABVC BioPharma posted an increased net loss in Q3 2025, driven by higher operating expenses, despite revenue growth and significant asset expansion through land acquisitions and debt reduction.

Summary

• Reported a net loss of $1,287,523 for the three months ended September 30, 2025, a 164% increase from $487,431 in the prior year period.
• For the nine months ended September 30, 2025, net loss increased by 2% to $4,564,546, compared to $4,462,510 in the same period of 2024.
• Revenues for the three months ended September 30, 2025, increased by 104% to $795,950, primarily from milestone payments from OncoX and ForSeeCon licensing agreements.
• Operating expenses surged by 184% to $1,964,360 for the three months ended September 30, 2025, mainly due to increased stock-based compensation for consultants and advisors.
• Working capital deficit improved significantly to $2,434,951 as of September 30, 2025, from $4,377,616 at December 31, 2024.
• Total assets increased substantially to $21,176,299 as of September 30, 2025, from $7,539,907 at December 31, 2024, largely due to land acquisitions.
• The Vitargus Phase II clinical study is on hold due to Serious Adverse Events (SAEs) observed in Thailand sites, prompting an investigation and product improvement efforts.
• The company completed the full repayment of its outstanding convertible notes with Lind Global Fund II, LP, through equity conversions and warrant exercises.
• Acquired land in Puli, Taiwan, with a carrying value of approximately $7.67 million, for future health-related business development, though title transfer is pending government review.
• Acquired land in Taoyuan City, Taiwan, from director Shuling Jiang for $3,857,975, paid with 2,035,136 restricted shares and 1,000,000 warrants, and assumed a $500,000 liability.
• Prior financial statements (2023, 2024) were restated to correct misstatements related to share-based payments, interest expenses, and non-controlling interest.
• A material weakness in disclosure controls and procedures was identified, which led to the restatement, and remediation efforts are underway.

Sentiment

Score: 3

Explanation: The company continues to report significant net losses and negative operating cash flows, raising substantial doubt about its going concern status. Key clinical trials face delays due to SAEs and funding issues. While there's revenue growth and a strengthened balance sheet from land acquisitions and debt reduction, these are overshadowed by ongoing operational challenges, internal control weaknesses, and Nasdaq compliance concerns.

Positives

• Revenue for the three months ended September 30, 2025, increased by 104% to $795,950 compared to $389,276 in the prior year.
• Revenue for the nine months ended September 30, 2025, increased by 57% to $795,950 compared to $507,623 in the prior year.
• Net loss per share for the nine months ended September 30, 2025, improved to $(0.23) from $(0.37) in the prior year, despite an increased net loss.
• Working capital deficit significantly reduced to $2,434,951 as of September 30, 2025, from $4,377,616 at December 31, 2024.
• Total assets increased substantially to $21,176,299 as of September 30, 2025, from $7,539,907 at December 31, 2024.
• Total equity increased significantly to $14,492,707 as of September 30, 2025, from $723,959 at December 31, 2024.
• Successfully completed full repayment of outstanding convertible notes with Lind Global Fund II, LP, reducing debt obligations and potential dilution.
• Regained compliance with Nasdaq's minimum stockholders' equity requirement (Rule 5550(b)(1)) as of May 5, 2025.
• Acquired two parcels of land in Taiwan for future health-related business development and manufacturing facilities, enhancing long-term operational capabilities.
• Received additional subscriptions totaling $507,833 post-period, indicating continued investor interest.

Negatives

• Net loss for the three months ended September 30, 2025, increased by 164% to $1,287,523 from $487,431 in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased by 2% to $4,564,546 from $4,462,510 in the prior year period.
• Operating expenses increased by 184% to $1,964,360 for the three months ended September 30, 2025, primarily due to higher stock-based compensation.
• Net cash used in operating activities increased by 42% to $1,567,264 for the nine months ended September 30, 2025, from $1,107,011 in the prior year.
• Net cash used in investing activities increased by 325% to $1,939,136 for the nine months ended September 30, 2025, from $456,789 in the prior year.
• The Vitargus Phase II clinical study is on hold due to Serious Adverse Events (SAEs) observed in Thailand sites.
• Development of ABV-2002 Corneal Storage Solution is temporarily suspended due to funding constraints.
• The company has a "substantial doubt" about its ability to continue as a going concern.
• A material weakness in disclosure controls and procedures was identified, leading to a restatement of prior financial statements.
• Still faces a Nasdaq minimum bid price compliance issue (Rule 5550(a)(2)), with a deadline of July 7, 2025.
• Fair value of FEYE and OncoX shares received as licensing fees is uncertain, preventing revenue recognition for these amounts.

Risks

• Substantial doubt exists about the ability to continue as a going concern due to net losses and negative operating cash flows.
• Inability to generate positive operating cash flows or raise additional capital may prevent meeting short-term obligations.
• The Vitargus Phase II study is on hold due to Serious Adverse Events (SAEs), requiring investigation and product improvements, which could delay or halt development.
• Development of ABV-2002 Corneal Storage Solution is on hold due to lack of funding.
• The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00 per share) and faces potential delisting if compliance is not achieved by July 7, 2025.
• A material weakness in disclosure controls and procedures led to a restatement of prior financial statements, which could continue to adversely impact reporting and financial obligations if not remediated.
• Licensing revenues from FEYE and OncoX shares are not recognized due to uncertain fair value, impacting reported revenue.
• Extensive related party transactions, including loans and land acquisitions, could pose conflicts of interest or financial risks.
• Legal restrictions in Taiwan prohibit foreign entities from directly owning farmland, complicating land acquisition and title transfer processes.
• The COVID-19 pandemic has adversely affected and is expected to continue to affect the CDMO business sector, with lab operations still below normal capacity.
• Competition in the industry could impact pricing, revenues, and margins.
• SEC regulations affecting trading in penny stocks may apply, potentially limiting safe harbor for forward-looking statements.
• Ability to protect technology and develop intellectual property.

Future Outlook

Management plans to improve operations to generate positive cash flows by ensuring full collection of cash consideration from licensing agreements, raising additional capital through private or public offerings, strictly controlling cash operating expenses, and reducing debts and interest expense. The company anticipates that ongoing affiliate integration and project execution will contribute positively to cash flows over the next 12 months. They also expect to initiate Phase I clinical study for ABV-1601 (Major Depression in Cancer Patients) around the end of 2025 and Phase I/II study for ABV-1519 (Non-Small Cell Lung Cancer) and Phase II for ABV-1703 (Advanced Inoperable or Metastatic Pancreatic Cancer) in Q4 2025.

Management Comments

• Managements plan is to continue to improve operations to generate positive cash flows and raise additional capital through private or public offerings, or financial support from related parties or shareholders.
• Management is committed to enhancing operations to generate positive cash flows to meet our operational needs.
• The Company is investigating the root causes of the events [SAEs in Vitargus study] and is working towards developing a safe device in-situ procedure before reinstating the study.
• The Company is currently evaluating further steps based on internal review and strategic alignment [for ABV-1505 ADHD study].
• The Board believes that this joint venture [BioLite Japan] will enhance the Companys ability to provide therapeutic solutions to significant unmet medical needs and to develop innovative botanical drugs to treat central nervous system (CNS) and oncology/ hematology diseases.
• The Companys Board of Directors believes that the joint venture has the potential to provide the Company with access to additional early-stage product candidates that it would not otherwise have access to and to introduce the Company to early-stage opportunities, and therefore the Board believes the joint venture is in the best interest of the Company and its shareholders.
• The company is negotiating on the licensing terms [for BioLite JP] and expects to conclude soon.
• We intend to actively monitor our stockholders equity and will consider options available to us to achieve compliance with Rule 5550.
• The Company is developing a plan to ensure that all information will be recorded, processed, summarized and reported accurately, and as of the date of this report, we are working to hire personnel with the requisite technical accounting knowledge to remediate the material weakness as soon as possible.

Industry Context

The company operates in the clinical-stage biopharmaceutical sector, focusing on plant-derived drugs and medical devices, a niche with historical successes like aspirin and Taxol. Its strategy of licensing drugs after Phase II trials to larger pharmaceutical companies is common for smaller biotechs to mitigate the high costs and risks of late-stage development and commercialization. The company's CDMO services also align with broader industry trends of outsourcing drug development and manufacturing. The mention of COVID-19 impact on lab access and research activity reflects a global challenge faced by the entire R&D-intensive pharmaceutical industry, with a hopeful outlook for recovery as vaccination programs progress. The focus on CNS, Hematology/Oncology, and Ophthalmology indicates targeting high-need therapeutic areas.

Comparison to Industry Standards

• The company's strategy of out-licensing drug candidates after Phase II clinical trials to major pharmaceutical companies for Phase III and commercialization is a standard practice for smaller biopharmaceutical companies to manage capital-intensive late-stage development and market entry.
• The reported net losses and negative operating cash flows are typical for clinical-stage biopharmaceutical companies that are heavily investing in R&D and have not yet brought products to market.
• The occurrence of Serious Adverse Events (SAEs) in a Phase II clinical trial (Vitargus) is a known risk in drug and medical device development, and the company's response of investigating root causes and improving the product is a standard procedure.
• The challenges with Nasdaq listing compliance, particularly regarding minimum bid price and stockholders' equity, are common for smaller, developing companies, and the company's efforts to regain compliance are standard.
• The restatement of financial statements due to accounting errors and material weaknesses in internal controls, while negative, highlights issues that can occur in companies with complex financial structures and growth, and the commitment to remediation is an expected response.

Management Changes

Corporate Governance

Legal Proceedings

• No pending or threatened claims and litigation that would have a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• **BioHopeKing Corporation (BHK):** Co-development agreements for BLI-1401-2 (TNBC), BLI-1005 (MDD), and BLI-1006 (IBD) with shared development costs and milestone payments. Company recognized $1 million in 2015 and $1 million in 2016. Entitled to 12% royalty on net sales. Due from BHK was $118,633 as of September 30, 2025, with expected credit losses recognized.
• **Rgene Corporation:** Co-development agreements for ABV-1507 (HER2/neu Breast Cancer), ABV-1511 (Pancreatic Cancer), ABV-1527 (Ovary Cancer), later amended to include ABV-1519 (EGFR NSCLC) and ABV-1526 (Colorectal Cancer). Company owns 37% of Rgene after convertible loan conversion. Provided clinical development services to Rgene for RGC-1501, RGC-1502, RGC-1503, eligible for $3.0 million over 3 years. Loaned $1.0 million and made $0.5 million to Rgene with a 5% interest rate convertible loan, fully converted in 2024 (Company owns additional 6.4% of Rgene). Due from Rgene was $2,421 as of September 30, 2025.
• **BioFirst Corporation:** Collaborative agreement for BFC-1401 Vitreous Substitute for Vitrectomy, later amended to add ABV-2001 and ABV-2002. Company to receive 50% of future net licensing income or net sales profit. Due from BioFirst was $2,691,776 as of September 30, 2025, including loans for working capital, research, facility construction, and regulatory work. Company owns 18.68% of BioFirst.
• **ForSeeCon Eye Corporation (FEYE):** Global licensing agreement for Ophthalmology pipeline (including Vitargus). Company to receive $33.5 million licensing fee (upfront $30 million in 5 million FEYE shares, $3.5 million cash milestone) and 5% royalties. Received 5 million FEYE shares but did not recognize revenue due to uncertain fair value. Received $200,000 in cash as partial milestone payment for nine months ended September 30, 2025. Company owns 19.78% of FEYE.
• **OncoX BioPharma, Inc.:** Definitive agreements for Lung Cancer Products, Pancreatic Product, Triple Negative Breast Cancer (TNBC) Product, and Myelodysplastic Syndrome (MS) Products. Each agreement involves $6.25 million (or 1.25 million OncoX shares) upfront and $625,000 cash milestone, plus 5% royalties. Received 1.25 million OncoX shares for each agreement but did not recognize revenue due to uncertain fair value. Received $595,950 in cash as partial milestone payment for nine months ended September 30, 2025. Company owns 24.97% of OncoX. Due from OncoX was $546 as of September 30, 2025.
• **Shuling Jiang (Director and >10% shareholder):** Acquired land in Taoyuan City, Taiwan, for $3,857,975, paid with 2,035,136 restricted shares and 1,000,000 warrants. Assumed $500,000 liability (promissory note at 3.79% interest). Entered a one-year consulting agreement for land-related services, issuing 1,000,000 restricted shares (5-year vesting, 200,000 shares/year).
• **AiBtl Holding:** Provided short-term loans to AiBtl totaling $348,194 as of September 30, 2025.
• **The Jiangs (Controlling beneficiary shareholder, Chairman, CEO, Director, etc.):** Advanced funds to the company for working capital ($79,846 due as of Sep 30, 2025).
• **Lion Arts Promotion, Inc.:** Consulting agreements for operation, business development, HR, capital finance, and international business development. Incurred $189,176 in consulting fees for nine months ended September 30, 2025. Accrued consulting services fee of $120,704 as of September 30, 2025.
• **BioLite Japan K.K.:** Joint venture for R&D, investment, and marketing in Japan. Company owns 49%. Paid $150,000 towards setup, fully impaired in 2024.
• **Landlord (California):** Issued common stock in lieu of cash for rent payments.

Stakeholder Impact

• **Shareholders:** Experience dilution from equity conversions of convertible notes and private offerings. Benefit from reduced debt and increased asset base. Face risks from ongoing losses, going concern doubt, clinical trial delays, and potential Nasdaq delisting.
• **Employees:** Impacted by management changes (CFO resignation). Stock-based compensation is a significant operating expense.
• **Customers:** BioKey's CDMO services continue, but COVID-19 impacts on lab capacity could affect service delivery.
• **Suppliers/Creditors:** Convertible note holders (Lind) have been repaid, reducing immediate credit risk. Other creditors (short-term loans, related parties) are still owed.
• **Regulatory Authorities (SEC, Nasdaq):** Company is subject to SEC reporting requirements and Nasdaq listing rules, with ongoing compliance issues (bid price) and internal control weaknesses requiring remediation.

Next Steps

• Investigate root causes of Serious Adverse Events (SAEs) in Vitargus Phase II study and develop a safe device in-situ procedure before reinstating the study.
• Evaluate further steps for the ABV-1505 (ADHD) clinical study based on internal review and strategic alignment.
• Initiate Phase I clinical study for ABV-1601 (Major Depression in Cancer Patients) around the end of 2025.
• Initiate Phase I/II study for ABV-1519 (Non-Small Cell Lung Cancer) in Q4 2025.
• Initiate Phase II study for ABV-1703 (Advanced Inoperable or Metastatic Pancreatic Cancer) in Q4 2025.
• Seek a partner (typically a large pharmaceutical company) to complete Phase III studies and commercialize drugs/medical devices upon successful completion of Phase II trials.
• Continue efforts to generate positive cash flows from operations.
• Raise additional capital through private or public offerings or financial support from related parties/shareholders.
• Strictly control cash operating expenses and reduce debts and interest expense.
• Remediate the material weakness in disclosure controls and procedures, including hiring personnel with requisite technical accounting knowledge.
• Actively monitor common stock bid price to regain compliance with Nasdaq Listing Rule 5550(a)(2) by July 7, 2025.
• Complete government review and title transfer for the Puli, Taiwan land acquisition to Yun Zhi Yi.
• Negotiate and conclude licensing terms for BioLite JP.

Key Dates

Recommendation

The company presents a mixed bag of significant risks and some strategic progress. The "substantial doubt" about its going concern status, persistent net losses, increased operating cash outflows, and the critical delay in the Vitargus Phase II trial due to SAEs are major red flags. The material weakness in internal controls and ongoing Nasdaq minimum bid price non-compliance add to the uncertainty. However, the company has shown some positive momentum with substantial asset growth through land acquisitions, a significant reduction in working capital deficit, and the successful repayment of convertible debt, which reduces future dilution risk. Revenue growth from licensing agreements, while not fully recognized due to fair value uncertainty, indicates potential future income streams. Given the high-risk profile of a clinical-stage biotech, compounded by financial and operational challenges, but also some strategic advancements and efforts to address issues, a "hold" recommendation is appropriate. Investors should monitor the resolution of the going concern issue, progress in clinical trials, remediation of internal control weaknesses, and Nasdaq compliance before considering further investment.

Keywords

Biopharma, Clinical Stage, Drug Development, Medical Devices, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue Growth, Operating Expenses, Working Capital, Going Concern, Nasdaq Compliance, Vitargus, ADHD, MDD, Oncology, Ophthalmology, Botanical Drugs, Clinical Trials, SAE, Land Acquisition, Convertible Notes, Capital Raise, Internal Controls, Restatement, Related Party Transactions, CDMO